Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | $6.07M | $6.36M | $11.2M | $3.89M | $0.00 | $0.00 | $0.00 |
| Revenue growth | — | — | — | — | 4.7% | 76.7% | -65.4% | -100.0% | — | — |
| Operating income | -$32.7M | -$39.9M | -$64.7M | -$88.2M | -$96.2M | -$130M | -$81.7M | -$39.7M | -$41.0M | -$39.2M |
| Operating margin | — | — | — | -1452.5% | -1512.6% | -1158.8% | -2099.3% | — | — | — |
| Net income | -$33.2M | -$42.2M | -$66.7M | -$94.3M | -$104M | -$143M | -$44.8M | -$42.2M | -$38.5M | -$27.0M |
| Net margin | — | — | — | -1553.3% | -1639.8% | -1268.7% | -1151.6% | — | — | — |
| EPS (diluted) | -$28.07 | -$3.71 | -$2.49 | -$2.76 | -$1.99 | -$108.32 | -$29.48 | -$17.35 | -$10.15 | -$3.31 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$27.3M | -$34.1M | -$54.1M | -$92.7M | -$90.7M | -$108M | -$78.9M | -$27.9M | -$29.4M | -$32.0M |
| Capital expenditures | $153K | $480K | $1.58M | $1.33M | — | — | — | — | — | — |
| Free cash flow | -$27.5M | -$34.6M | -$55.7M | -$94.1M | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $45.6M | $115M | $183M | $85.4M | $77.3M | $92.1M | $70.5M | $50.9M | $51.2M | $7.56M |
| Total assets | $46.3M | $117M | $221M | $154M | $222M | $139M | $86.8M | $55.9M | $55.5M | $9.49M |
| Total liabilities | $15.7M | $26.9M | $116M | $125M | $122M | $123M | $67.8M | $48.4M | $43.2M | $2.49M |
| Long-term debt | $9.10M | $12.0M | $70.2M | $71.2M | $72.2M | $78.9M | $37.9M | $34.2M | $20.1M | — |
| Shareholders' equity | -$87.8M | $89.7M | $105M | $29.7M | $100.0M | $16.8M | $19.0M | $7.50M | $12.3M | $7.00M |
| Retained earnings | -$92.1M | -$134M | -$201M | -$295M | -$400M | -$542M | -$587M | -$629M | -$668M | -$695M |
| Shares (wtd avg diluted) | 1.18M | 24.5M | 33.9M | 36.1M | 52.4M | 1.32M | 1.52M | 2.43M | 3.80M | 8.15M |
Every figure is extracted from KALA BIO, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.